Overnight Market report, page-2521

Topline TACTI-003 data soon, which will be the 2nd randomized placebo controlled study for eftilagimod alpha. I still have PTSD, and recall the enthusiasm prior to AIPAC data was enormous. I’m not feeling enthusiasm for TACTI-003 HNSCC, with ph3 1st line NSCLC getting top billing in the recent investor update. That’s increasing my PTSD, because successfully demonstrating efti activity should be the biggest event in history. Positive data proves the hypothesis and implies what will happen in other indications like NSCLC. Let’s hope it’s just cool confidence, letting the data speak for itself.